25 XP   0   0   10

Celon Pharma SA
Buy, Hold or Sell?

Let's analyse Celon Pharma SA together

PenkeI guess you are interested in Celon Pharma SA. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Celon Pharma SA. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Celon Pharma SA

I send you an email if I find something interesting about Celon Pharma SA.

Quick analysis of Celon Pharma SA (30 sec.)










What can you expect buying and holding a share of Celon Pharma SA? (30 sec.)

How much money do you get?

How much money do you get?
zł0.00
When do you have the money?
1 year
How often do you get paid?
70.6%

What is your share worth?

Current worth
zł9.01
Expected worth in 1 year
zł8.39
How sure are you?
47.1%

+ What do you gain per year?

Total Gains per Share
zł-0.62
Return On Investment
-4.1%

For what price can you sell your share?

Current Price per Share
zł15.12
Expected price per share
zł14.00 - zł16.10
How sure are you?
50%

1. Valuation of Celon Pharma SA (5 min.)




Live pricePrice per Share (EOD)

zł15.12

Intrinsic Value Per Share

zł38.12 - zł46.11

Total Value Per Share

zł47.13 - zł55.12

2. Growth of Celon Pharma SA (5 min.)




Is Celon Pharma SA growing?

Current yearPrevious yearGrowGrow %
How rich?$115.3m$130.3m-$12.8m-11.0%

How much money is Celon Pharma SA making?

Current yearPrevious yearGrowGrow %
Making money-$1.1m-$1.9m$767k64.0%
Net Profit Margin-11.5%-20.2%--

How much money comes from the company's main activities?

3. Financial Health of Celon Pharma SA (5 min.)




What can you expect buying and holding a share of Celon Pharma SA? (5 min.)

Welcome investor! Celon Pharma SA's management wants to use your money to grow the business. In return you get a share of Celon Pharma SA.

What can you expect buying and holding a share of Celon Pharma SA?

First you should know what it really means to hold a share of Celon Pharma SA. And how you can make/lose money.

Speculation

The Price per Share of Celon Pharma SA is zł15.12. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Celon Pharma SA.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Celon Pharma SA, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is zł9.01. Based on the TTM, the Book Value Change Per Share is zł-0.15 per quarter. Based on the YOY, the Book Value Change Per Share is zł-0.34 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is zł0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Celon Pharma SA.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.03-0.2%-0.04-0.2%-0.04-0.3%-0.02-0.1%-0.02-0.1%
Usd Book Value Change Per Share-0.03-0.2%-0.04-0.3%-0.09-0.6%0.130.9%0.130.9%
Usd Dividend Per Share0.000.0%0.000.0%0.070.5%0.030.2%0.030.2%
Usd Total Gains Per Share-0.03-0.2%-0.04-0.3%-0.01-0.1%0.161.1%0.161.1%
Usd Price Per Share3.84-3.75-5.47-7.57-7.57-
Price to Earnings Ratio-28.66--7.74--46.53-16.28-16.28-
Price-to-Total Gains Ratio-120.64--173.55-56.35--40.00--40.00-
Price to Book Ratio1.70-1.63-2.11-3.71-3.71-
Price-to-Total Gains Ratio-120.64--173.55-56.35--40.00--40.00-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.790584
Number of shares263
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.03
Usd Book Value Change Per Share-0.040.13
Usd Total Gains Per Share-0.040.16
Gains per Quarter (263 shares)-10.1542.04
Gains per Year (263 shares)-40.59168.16
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-41-5128140158
20-81-9257280326
30-122-13385419494
40-162-174114559662
50-203-215142699830
60-244-256170839998
70-284-2971999781166
80-325-33822711181334
90-365-37925512581502
100-406-42028413981670

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%2.010.00.016.7%6.011.00.035.3%6.011.00.035.3%6.011.00.035.3%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%5.012.00.029.4%5.012.00.029.4%5.012.00.029.4%
Dividend per Share0.00.04.00.0%8.00.04.066.7%12.00.05.070.6%12.00.05.070.6%12.00.05.070.6%
Total Gains per Share0.04.00.00.0%4.08.00.033.3%8.09.00.047.1%8.09.00.047.1%8.09.00.047.1%

Fundamentals of Celon Pharma SA

About Celon Pharma SA

Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. operates as a subsidiary of Glatton Sp. z o.o.

Fundamental data was last updated by Penke on 2024-03-19 10:50:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is underpriced.

1.1. Profitability of Celon Pharma SA.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Celon Pharma SA earns for each zł1 of revenue.

  • Above 10% is considered healthy but always compare Celon Pharma SA to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -16.0% means that zł-0.16 for each zł1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Celon Pharma SA:

  • The MRQ is -16.0%. The company is making a huge loss. -2
  • The TTM is -11.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-16.0%TTM-11.5%-4.6%
TTM-11.5%YOY-20.2%+8.8%
TTM-11.5%5Y-7.9%-3.6%
5Y-7.9%10Y-7.9%0.0%
1.1.2. Return on Assets

Shows how efficient Celon Pharma SA is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Celon Pharma SA to the Drug Manufacturers - Specialty & Generic industry mean.
  • -1.2% Return on Assets means that Celon Pharma SA generated zł-0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Celon Pharma SA:

  • The MRQ is -1.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -0.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-1.2%TTM-0.8%-0.4%
TTM-0.8%YOY-1.2%+0.4%
TTM-0.8%5Y-0.5%-0.3%
5Y-0.5%10Y-0.5%0.0%
1.1.3. Return on Equity

Shows how efficient Celon Pharma SA is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Celon Pharma SA to the Drug Manufacturers - Specialty & Generic industry mean.
  • -1.5% Return on Equity means Celon Pharma SA generated zł-0.01 for each zł1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Celon Pharma SA:

  • The MRQ is -1.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -1.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-1.5%TTM-1.0%-0.5%
TTM-1.0%YOY-1.5%+0.5%
TTM-1.0%5Y-0.6%-0.4%
5Y-0.6%10Y-0.6%0.0%

1.2. Operating Efficiency of Celon Pharma SA.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Celon Pharma SA is operating .

  • Measures how much profit Celon Pharma SA makes for each zł1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Celon Pharma SA to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated zł0.00  for each zł1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Celon Pharma SA:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-6.1%+6.1%
TTM-6.1%YOY-24.5%+18.3%
TTM-6.1%5Y-5.8%-0.3%
5Y-5.8%10Y-5.8%0.0%
1.2.2. Operating Ratio

Measures how efficient Celon Pharma SA is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.63 means that the operating costs are zł1.63 for each zł1 in net sales.

Let's take a look of the Operating Ratio trends of Celon Pharma SA:

  • The MRQ is 1.632. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.520. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.632TTM1.520+0.111
TTM1.520YOY1.674-0.154
TTM1.5205Y1.123+0.397
5Y1.12310Y1.1230.000

1.3. Liquidity of Celon Pharma SA.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Celon Pharma SA is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.74 means the company has zł1.74 in assets for each zł1 in short-term debts.

Let's take a look of the Current Ratio trends of Celon Pharma SA:

  • The MRQ is 1.744. The company is able to pay all its short-term debts. +1
  • The TTM is 2.039. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.744TTM2.039-0.295
TTM2.039YOY2.935-0.896
TTM2.0395Y2.580-0.540
5Y2.58010Y2.5800.000
1.3.2. Quick Ratio

Measures if Celon Pharma SA is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Celon Pharma SA to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.14 means the company can pay off zł1.14 for each zł1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Celon Pharma SA:

  • The MRQ is 1.139. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.195. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.139TTM1.195-0.056
TTM1.195YOY1.262-0.068
TTM1.1955Y1.609-0.414
5Y1.60910Y1.6090.000

1.4. Solvency of Celon Pharma SA.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Celon Pharma SA assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Celon Pharma SA to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.20 means that Celon Pharma SA assets are financed with 20.0% credit (debt) and the remaining percentage (100% - 20.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Celon Pharma SA:

  • The MRQ is 0.200. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.216. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.200TTM0.216-0.017
TTM0.216YOY0.227-0.011
TTM0.2165Y0.253-0.037
5Y0.25310Y0.2530.000
1.4.2. Debt to Equity Ratio

Measures if Celon Pharma SA is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Celon Pharma SA to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 25.0% means that company has zł0.25 debt for each zł1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Celon Pharma SA:

  • The MRQ is 0.250. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.277. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.250TTM0.277-0.027
TTM0.277YOY0.294-0.018
TTM0.2775Y0.344-0.068
5Y0.34410Y0.3440.000

2. Market Valuation of Celon Pharma SA

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every zł1 in earnings Celon Pharma SA generates.

  • Above 15 is considered overpriced but always compare Celon Pharma SA to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -28.66 means the investor is paying zł-28.66 for every zł1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Celon Pharma SA:

  • The EOD is -28.319. Based on the earnings, the company is expensive. -2
  • The MRQ is -28.656. Based on the earnings, the company is expensive. -2
  • The TTM is -7.736. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-28.319MRQ-28.656+0.337
MRQ-28.656TTM-7.736-20.920
TTM-7.736YOY-46.529+38.794
TTM-7.7365Y16.283-24.019
5Y16.28310Y16.2830.000
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Celon Pharma SA:

  • The EOD is 91.164. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The MRQ is 92.249. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is 22.623. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD91.164MRQ92.249-1.085
MRQ92.249TTM22.623+69.626
TTM22.623YOY-2.177+24.800
TTM22.6235Y-14.207+36.830
5Y-14.20710Y-14.2070.000
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Celon Pharma SA is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 1.70 means the investor is paying zł1.70 for each zł1 in book value.

Let's take a look of the Price to Book Ratio trends of Celon Pharma SA:

  • The EOD is 1.678. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.698. Based on the equity, the company is underpriced. +1
  • The TTM is 1.631. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.678MRQ1.698-0.020
MRQ1.698TTM1.631+0.068
TTM1.631YOY2.111-0.481
TTM1.6315Y3.709-2.079
5Y3.70910Y3.7090.000
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Celon Pharma SA compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.127-0.154+21%-0.341+169%0.530-124%0.530-124%
Book Value Per Share--9.0109.178-2%10.183-12%8.690+4%8.690+4%
Current Ratio--1.7442.039-14%2.935-41%2.580-32%2.580-32%
Debt To Asset Ratio--0.2000.216-8%0.227-12%0.253-21%0.253-21%
Debt To Equity Ratio--0.2500.277-10%0.294-15%0.344-27%0.344-27%
Dividend Per Share----0%0.290-100%0.108-100%0.108-100%
Eps---0.133-0.140+5%-0.154+15%-0.074-45%-0.074-45%
Free Cash Flow Per Share--0.041-0.151+465%-0.189+555%-0.334+906%-0.334+906%
Free Cash Flow To Equity Per Share--0.041-0.235+666%-0.317+865%-0.193+565%-0.193+565%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--46.110--------
Intrinsic Value_10Y_min--38.117--------
Intrinsic Value_1Y_max--0.316--------
Intrinsic Value_1Y_min--0.307--------
Intrinsic Value_3Y_max--4.229--------
Intrinsic Value_3Y_min--3.971--------
Intrinsic Value_5Y_max--12.098--------
Intrinsic Value_5Y_min--10.947--------
Market Cap771974280.000-1%781164450.000763549957.500+2%1114946318.750-30%1540765037.059-49%1540765037.059-49%
Net Profit Margin---0.160-0.115-29%-0.202+26%-0.079-51%-0.079-51%
Operating Margin----0.0610%-0.2450%-0.0580%-0.0580%
Operating Ratio--1.6321.520+7%1.674-3%1.123+45%1.123+45%
Pb Ratio1.678-1%1.6981.631+4%2.111-20%3.709-54%3.709-54%
Pe Ratio-28.319+1%-28.656-7.736-73%-46.529+62%16.283-276%16.283-276%
Price Per Share15.120-1%15.30014.955+2%21.838-30%30.178-49%30.178-49%
Price To Free Cash Flow Ratio91.164-1%92.24922.623+308%-2.177+102%-14.207+115%-14.207+115%
Price To Total Gains Ratio-119.224+1%-120.643-173.552+44%56.351-314%-39.997-67%-39.997-67%
Quick Ratio--1.1391.195-5%1.262-10%1.609-29%1.609-29%
Return On Assets---0.012-0.008-34%-0.0120%-0.005-58%-0.005-58%
Return On Equity---0.015-0.010-32%-0.015+4%-0.006-57%-0.006-57%
Total Gains Per Share---0.127-0.154+21%-0.051-60%0.638-120%0.638-120%
Usd Book Value--115323754.900117477581.275-2%130344508.075-12%111229025.937+4%111229025.937+4%
Usd Book Value Change Per Share---0.032-0.039+21%-0.085+169%0.133-124%0.133-124%
Usd Book Value Per Share--2.2592.301-2%2.553-12%2.179+4%2.179+4%
Usd Dividend Per Share----0%0.073-100%0.027-100%0.027-100%
Usd Eps---0.033-0.035+5%-0.039+15%-0.019-45%-0.019-45%
Usd Free Cash Flow--530731.900-1936657.500+465%-2415619.850+555%-4276888.581+906%-4276888.581+906%
Usd Free Cash Flow Per Share--0.010-0.038+465%-0.047+555%-0.084+906%-0.084+906%
Usd Free Cash Flow To Equity Per Share--0.010-0.059+666%-0.080+865%-0.048+565%-0.048+565%
Usd Market Cap193533951.996-1%195837927.615191421974.345+2%279517042.111-30%386269794.791-49%386269794.791-49%
Usd Price Per Share3.791-1%3.8363.749+2%5.475-30%7.566-49%7.566-49%
Usd Profit---1708520.500-1199098.100-30%-1966114.750+15%-806522.251-53%-806522.251-53%
Usd Revenue--10654750.00010522505.750+1%9836527.875+8%9969978.582+7%9969978.582+7%
Usd Total Gains Per Share---0.032-0.039+21%-0.013-60%0.160-120%0.160-120%
 EOD+4 -4MRQTTM+19 -13YOY+18 -165Y+14 -2010Y+14 -20

3.2. Fundamental Score

Let's check the fundamental score of Celon Pharma SA based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-28.319
Price to Book Ratio (EOD)Between0-11.678
Net Profit Margin (MRQ)Greater than0-0.160
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.139
Current Ratio (MRQ)Greater than11.744
Debt to Asset Ratio (MRQ)Less than10.200
Debt to Equity Ratio (MRQ)Less than10.250
Return on Equity (MRQ)Greater than0.15-0.015
Return on Assets (MRQ)Greater than0.05-0.012
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Celon Pharma SA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.958
Ma 20Greater thanMa 5015.121
Ma 50Greater thanMa 10015.142
Ma 100Greater thanMa 20015.229
OpenGreater thanClose15.140
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in PLN. All numbers in thousands.

Summary
Total Assets574,886
Total Liabilities114,879
Total Stockholder Equity460,007
 As reported
Total Liabilities 114,879
Total Stockholder Equity+ 460,007
Total Assets = 574,886

Assets

Total Assets574,886
Total Current Assets177,792
Long-term Assets397,094
Total Current Assets
Cash And Cash Equivalents 21,919
Short-term Investments 80,029
Net Receivables 36,068
Inventory 29,809
Other Current Assets 1,398
Total Current Assets  (as reported)177,792
Total Current Assets  (calculated)169,223
+/- 8,569
Long-term Assets
Property Plant Equipment 342,087
Intangible Assets 16,428
Long-term Assets Other 341
Long-term Assets  (as reported)397,094
Long-term Assets  (calculated)358,856
+/- 38,238

Liabilities & Shareholders' Equity

Total Current Liabilities101,927
Long-term Liabilities12,952
Total Stockholder Equity460,007
Total Current Liabilities
Accounts payable 17,758
Other Current Liabilities 36,451
Total Current Liabilities  (as reported)101,927
Total Current Liabilities  (calculated)54,209
+/- 47,718
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt16,611
Long-term Liabilities  (as reported)12,952
Long-term Liabilities  (calculated)16,611
+/- 3,659
Total Stockholder Equity
Total Stockholder Equity (as reported)460,007
Total Stockholder Equity (calculated)0
+/- 460,007
Other
Capital Stock5,106
Common Stock Shares Outstanding 51,057
Net Invested Capital 460,007
Net Working Capital 75,865
Property Plant and Equipment Gross 566,482



Balance Sheet

Currency in PLN. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-30
> Total Assets 
581,494
591,346
449,634
497,875
512,225
531,888
560,276
537,552
710,540
707,138
676,260
666,057
640,761
608,935
618,070
591,233
574,886
574,886591,233618,070608,935640,761666,057676,260707,138710,540537,552560,276531,888512,225497,875449,634591,346581,494
   > Total Current Assets 
155,351
143,576
126,656
101,484
104,803
118,917
119,342
101,230
284,791
278,701
263,428
259,374
234,269
237,581
209,285
188,109
177,792
177,792188,109209,285237,581234,269259,374263,428278,701284,791101,230119,342118,917104,803101,484126,656143,576155,351
       Cash And Cash Equivalents 
78,123
66,692
29,527
16,886
29,620
43,978
41,307
25,005
218,283
147,796
124,514
113,167
77,811
82,902
49,819
25,061
21,919
21,91925,06149,81982,90277,811113,167124,514147,796218,28325,00541,30743,97829,62016,88629,52766,69278,123
       Short-term Investments 
0
0
0
0
0
0
13
0
0
79,755
79,353
78,672
80,363
81,722
84,412
86,830
80,029
80,02986,83084,41281,72280,36378,67279,35379,7550013000000
       Net Receivables 
33,075
38,918
30,938
46,588
37,423
42,034
45,645
43,043
34,841
27,245
28,304
35,516
37,357
27,111
28,053
42,937
36,068
36,06842,93728,05327,11137,35735,51628,30427,24534,84143,04345,64542,03437,42346,58830,93838,91833,075
       Inventory 
28,164
30,062
27,864
26,852
29,029
29,760
29,238
27,106
30,373
23,376
29,458
29,921
36,681
38,385
38,313
30,355
29,809
29,80930,35538,31338,38536,68129,92129,45823,37630,37327,10629,23829,76029,02926,85227,86430,06228,164
       Other Current Assets 
2,972
1,044
2,817
2,161
1,977
3,145
3,139
6,076
1,294
529
1,799
2,098
2,057
871
2,630
2,926
1,398
1,3982,9262,6308712,0572,0981,7995291,2946,0763,1393,1451,9772,1612,8171,0442,972
   > Long-term Assets 
0
0
0
0
0
584,725
440,934
436,323
425,749
428,437
412,832
406,683
406,492
371,354
408,785
403,124
397,094
397,094403,124408,785371,354406,492406,683412,832428,437425,749436,323440,934584,72500000
       Property Plant Equipment 
232,239
242,785
266,859
294,566
309,881
311,530
333,851
324,417
318,496
316,571
315,605
316,451
332,948
306,794
347,445
348,377
342,087
342,087348,377347,445306,794332,948316,451315,605316,571318,496324,417333,851311,530309,881294,566266,859242,785232,239
       Intangible Assets 
6,561
6,162
20,745
56,941
54,370
41,096
38,523
35,418
29,416
29,171
27,570
26,255
24,291
28,121
19,877
17,741
16,428
16,42817,74119,87728,12124,29126,25527,57029,17129,41635,41838,52341,09654,37056,94120,7456,1626,561
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
379
388
364
341
3413643883790000000000000
> Total Liabilities 
136,588
146,305
103,742
142,676
158,028
187,356
189,043
171,221
149,498
153,136
145,348
162,717
149,326
129,289
149,812
124,751
114,879
114,879124,751149,812129,289149,326162,717145,348153,136149,498171,221189,043187,356158,028142,676103,742146,305136,588
   > Total Current Liabilities 
23,040
25,983
67,996
58,222
106,913
70,570
115,174
100,791
84,373
86,363
79,931
101,682
87,844
116,440
102,305
80,843
101,927
101,92780,843102,305116,44087,844101,68279,93186,36384,373100,791115,17470,570106,91358,22267,99625,98323,040
       Short Long Term Debt 
0
0
0
0
0
12,837
13,240
12,307
0
0
0
2
0
0
0
0
0
00000200012,30713,24012,83700000
       Accounts payable 
0
0
0
0
0
18,092
21,853
21,344
12,564
11,872
18,257
16,308
31,507
18,306
19,902
13,667
17,758
17,75813,66719,90218,30631,50716,30818,25711,87212,56421,34421,85318,09200000
       Other Current Liabilities 
0
0
0
0
0
32,500
70,824
51,827
58,266
64,814
47,695
51,792
38,990
14,396
12,278
45,433
36,451
36,45145,43312,27814,39638,99051,79247,69564,81458,26651,82770,82432,50000000
   > Long-term Liabilities 
0
0
0
0
0
198,401
73,872
70,429
65,125
66,773
65,417
61,035
61,482
12,849
47,507
43,908
12,952
12,95243,90847,50712,84961,48261,03565,41766,77365,12570,42973,872198,40100000
       Other Liabilities 
0
0
0
0
0
191,067
64,469
61,767
56,421
58,419
55,185
52,580
50,870
0
0
37,459
0
037,4590050,87052,58055,18558,41956,42161,76764,469191,06700000
       Deferred Long Term Liability 
0
0
0
0
0
2,720
0
0
0
1,360
1,020
680
680
0
0
0
0
00006806801,0201,3600002,72000000
> Total Stockholder Equity
444,906
445,040
345,892
355,199
354,197
344,532
371,233
366,331
561,042
554,002
530,912
503,340
491,435
479,646
468,258
466,482
460,007
460,007466,482468,258479,646491,435503,340530,912554,002561,042366,331371,233344,532354,197355,199345,892445,040444,906
   Common Stock
4,500
4,500
4,500
4,500
4,500
4,500
4,500
4,500
5,100
5,100
5,100
5,103
5,104
0
0
5,106
0
05,106005,1045,1035,1005,1005,1004,5004,5004,5004,5004,5004,5004,5004,500
   Retained Earnings 
170,701
172,342
336,588
336,449
338,261
190,237
-60,289
-79,766
-87,596
-91,674
-99,187
-107,741
-107,803
-119,788
-129,263
-86,850
-93,666
-93,666-86,850-129,263-119,788-107,803-107,741-99,187-91,674-87,596-79,766-60,289190,237338,261336,449336,588172,342170,701
   Capital Surplus 
234,452
234,452
0
234,452
234,452
0
0
0
0
0
0
0
0
0
0
0
0
000000000000234,452234,4520234,452234,452
   Treasury Stock00000000000000000
   Other Stockholders Equity 
0
0
-1
0
0
5,482
33,898
30,128
30,028
27,066
11,489
7,268
7,030
0
0
4,994
0
04,994007,0307,26811,48927,06630,02830,12833,8985,48200-100



Balance Sheet

Currency in PLN. All numbers in thousands.




Cash Flow

Currency in PLN. All numbers in thousands.




Income Statement

Currency in PLN. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue167,890
Cost of Revenue-69,492
Gross Profit98,39898,398
 
Operating Income (+$)
Gross Profit98,398
Operating Expense-194,499
Operating Income-26,609-96,101
 
Operating Expense (+$)
Research Development-
Selling General Administrative-
Selling And Marketing Expenses-
Operating Expense194,4990
 
Net Interest Income (+$)
Interest Income1,065
Interest Expense-2,589
Other Finance Cost-1,018
Net Interest Income-506
 
Pretax Income (+$)
Operating Income-26,609
Net Interest Income-506
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-17,401-26,609
EBIT - interestExpense = -2,589
-25,140
-22,551
Interest Expense2,589
Earnings Before Interest and Taxes (EBIT)--14,812
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-17,401
Tax Provision-7,739
Net Income From Continuing Ops-25,140-25,140
Net Income-25,140
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-506
 

Technical Analysis of Celon Pharma SA
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Celon Pharma SA. The general trend of Celon Pharma SA is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Celon Pharma SA's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Celon Pharma SA.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 15.82 < 15.90 < 16.10.

The bearish price targets are: 14.90 > 14.62 > 14.00.

Tweet this
Celon Pharma SA Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Celon Pharma SA. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Celon Pharma SA Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Celon Pharma SA. The current macd is -0.04010751.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Celon Pharma SA price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Celon Pharma SA. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Celon Pharma SA price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Celon Pharma SA Daily Moving Average Convergence/Divergence (MACD) ChartCelon Pharma SA Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Celon Pharma SA. The current adx is 12.04.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Celon Pharma SA shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Celon Pharma SA Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Celon Pharma SA. The current sar is 15.69.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Celon Pharma SA Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Celon Pharma SA. The current rsi is 49.96. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Celon Pharma SA Daily Relative Strength Index (RSI) ChartCelon Pharma SA Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Celon Pharma SA. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Celon Pharma SA price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Celon Pharma SA Daily Stochastic Oscillator ChartCelon Pharma SA Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Celon Pharma SA. The current cci is -6.25.

Celon Pharma SA Daily Commodity Channel Index (CCI) ChartCelon Pharma SA Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Celon Pharma SA. The current cmo is 1.77646963.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Celon Pharma SA Daily Chande Momentum Oscillator (CMO) ChartCelon Pharma SA Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Celon Pharma SA. The current willr is -59.3220339.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Celon Pharma SA is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Celon Pharma SA Daily Williams %R ChartCelon Pharma SA Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Celon Pharma SA.

Celon Pharma SA Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Celon Pharma SA. The current atr is 0.35218441.

Celon Pharma SA Daily Average True Range (ATR) ChartCelon Pharma SA Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Celon Pharma SA. The current obv is 258,129.

Celon Pharma SA Daily On-Balance Volume (OBV) ChartCelon Pharma SA Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Celon Pharma SA. The current mfi is 60.19.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Celon Pharma SA Daily Money Flow Index (MFI) ChartCelon Pharma SA Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Celon Pharma SA.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-09STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-11-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-14STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-11-17STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-11-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-14RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-23WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-27WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.

6.3. Candlestick Patterns

Celon Pharma SA Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Celon Pharma SA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.958
Ma 20Greater thanMa 5015.121
Ma 50Greater thanMa 10015.142
Ma 100Greater thanMa 20015.229
OpenGreater thanClose15.140
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Celon Pharma SA with someone you think should read this too:
  • Are you bullish or bearish on Celon Pharma SA? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Celon Pharma SA? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Celon Pharma SA

I send you an email if I find something interesting about Celon Pharma SA.


Comments

How you think about this?

Leave a comment

Stay informed about Celon Pharma SA.

Receive notifications about Celon Pharma SA in your mailbox!